Cancer is a complex disease driven by somatic mutations accumulating within cells, leading to uncontrolled proliferation and metastasis.  Advances in genomic technologies have revolutionized our understanding of the genetic basis of cancer, revealing a heterogeneous landscape of driver mutations across various cancer types.  Next-generation sequencing (NGS) now enables comprehensive profiling of tumor genomes, transcriptomes, and epigenomes, identifying specific genetic alterations that contribute to oncogenesis. This wealth of data fuels the development of personalized medicine approaches, tailoring cancer therapies to the unique genetic profile of each patient.  Targeted therapies, designed to inhibit the activity of specific oncogenes or restore the function of tumor suppressor genes, show improved efficacy and reduced toxicity compared to conventional chemotherapy.  Furthermore, immunotherapies, such as checkpoint inhibitors, are being refined based on genomic characteristics predicting response.  While challenges remain, including the identification of actionable targets, the development of robust predictive biomarkers, and managing treatment resistance, the integration of genomic data with clinical information is driving significant progress in the prevention, diagnosis, and treatment of cancer, paving the way for truly personalized cancer care.  Future research should focus on refining predictive models, incorporating multi-omics data, and understanding the interplay between genetic alterations and the tumor microenvironment to further enhance the effectiveness of personalized cancer therapies.